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Abstract
Background
Colorectal cancer (CRC) is a major cause of worldwide morbidity and mortality. Surgical
treatment is common, and there is a great need to improve the delivery of such care. The
gold standard for evaluating surgery is within well-designed randomized controlled trials
(RCTs); however, the impact of RCTs is diminished by a lack of coordinated outcome mea-
surement and reporting. A solution to these issues is to develop an agreed standard “core”
set of outcomes to be measured in all trials to facilitate cross-study comparisons, meta-anal-
ysis, and minimize outcome reporting bias. This study defines a core outcome set for CRC
surgery.
Methods and Findings
The scope of this COS includes clinical effectiveness trials of surgical interventions for colo-
rectal cancer. Excluded were nonsurgical oncological interventions. Potential outcomes of
importance to patients and professionals were identified through systematic literature
reviews and patient interviews. All outcomes were transcribed verbatim and categorized
into domains by two independent researchers. This informed a questionnaire survey that
asked stakeholders (patients and professionals) from United Kingdom CRC centers to rate
the importance of each domain. Respondents were resurveyed following group feedback
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(Delphi methods). Outcomes rated as less important were discarded after each survey
round according to predefined criteria, and remaining outcomes were considered at three
consensus meetings; two involving international professionals and a separate one with
patients. A modified nominal group technique was used to gain the final consensus. Data
sources identified 1,216 outcomes of CRC surgery that informed a 91 domain question-
naire. First round questionnaires were returned from 63 out of 81 (78%) centers, including
90 professionals, and 97 out of 267 (35%) patients. Second round response rates were high
for all stakeholders (>80%). Analysis of responses lead to 45 and 23 outcome domains
being retained after the first and second surveys, respectively. Consensus meetings gener-
ated agreement on a 12 domain COS. This constituted five perioperative outcome domains
(including anastomotic leak), four quality of life outcome domains (including fecal urgency
and incontinence), and three oncological outcome domains (including long-term survival).
Conclusion
This study used robust consensus methodology to develop a core outcome set for use in
colorectal cancer surgical trials. It is now necessary to validate the use of this set in research
practice.
Background
Randomized controlled trials (RCTs) represent the gold standard in evaluating health care
interventions. They aim to produce high quality evidence that can be used to inform clinical
care; however, the clinical impact of RCTs is diminished by of a lack of coordination of out-
come measurement and reporting. Indeed, multiple systematic reviews throughout many dif-
ferent branches of medicine have been consistent in demonstrating the large number and
heterogeneity of outcome reporting in trials and other research studies [1–4]. This has the
effect of making clinically relevant comparisons between trials and pooling of results in meta-
analyses difficult. Furthermore, multiplicity of outcome measurement can lead to the selective
reporting of significant findings in the form of outcome reporting bias [5].
A proposed solution to these issues is to develop and use “core outcome sets” (COSs). A
COS is a minimum set of outcomes that key stakeholders agree to be measured in all trials in a
particular field [6]. This approach allows a consistent set of outcomes to be measured and has
the potential to improve the efficiency with which research can answer clinical questions. The
benefits of COSs have now been embraced internationally by funding bodies [6], regulatory
bodies [7,8], and journal editors [9], all of which recommend their use where available. As a
result, the development of COSs is increasingly common. The COMET (Core Outcome Mea-
sures in Effectiveness Trials) initiative has recorded nearly 600 published or ongoing studies
into COSs, and many have now been developed in diverse clinical areas including rheumatol-
ogy [10], pediatrics [11], and obstetrics [12]. There is, however, no established COS for colorec-
tal cancer (CRC) surgery.
This is now urgently needed, because CRC surgery is undergoing a period of intense innova-
tion. CRC is a major cause of worldwide morbidity and mortality, representing the third most
common cancer and fourth most common cause of cancer death [13]. Surgery is a fundamental
method for both curative and palliative treatment of this disease, and there is therefore a great
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need to improve the delivery of such care [14]. The last decade has seen several RCTs of laparo-
scopic techniques, all of which have measured different outcomes and thus suffer from the
weaknesses described above [15,16]. The future will include evaluations of robotic surgery,
transanal resection of the rectum, and organ-preserving rectal surgery, all of which have the
potential to improve the care of many patients with CRC, provided they are evaluated in a
robust and efficient manner. The aim of this study is therefore to define a COS for use in trials
and other studies in CRC surgery, agreed upon by patients and CRC professionals.
Methods
The scope of this COS includes clinical effectiveness trials (rather than trials of treatment effi-
cacy) of all surgical interventions for cancer of the colon and rectum. Excluded were oncologi-
cal interventions. The COS defines which outcomes are recommended, but does not specify
how they should be measured. The COS could also be used in audit and nonrandomized stud-
ies of CRC.
The development of the COS was conducted in three phases according to COMET guide-
lines [6]. In Phase 1, a long list of outcomes that could be measured in CRC trials was identi-
fied, and outcomes were categorized into domains. In Phase 2, domains were operationalized
into a questionnaire that was used to survey stakeholders’ views on the importance of each
domain using Delphi methods. In Phase 3, consensus meetings with patients and surgeons
were used to finalize the core set. Appropriate ethics regulatory approval was granted (National
Research Ethics Service number 10/H0102/82).
Phase 1: Domain Generation
Outcomes of CRC surgery were identified from three sources; i) systematic review of clinical
and patient-reported outcome literature [17,18]; ii) interviews with patients; and iii) analysis of
written patient information leaflets used for colorectal surgery in hospitals in the United King-
dom. Duplicates were removed, and a long list of outcomes was created. Similar outcomes were
categorized into domains by two members of the study team. Patient-reported outcomes were
grouped into domains (e.g., ability to walk and activity levels were grouped within the physical
function domain) and verified by two researchers and a patient representative [19]. Items from
patient information leaflets were independently categorized by two surgeons. Discrepancies
were resolved through discussion with the study lead. Overlapping domains between data
sources were condensed, producing a final list of domains.
The final domains were operationalized into questionnaire items using lay language with
the medical terminology included in parentheses. The questionnaire was piloted by patients for
face validity, understanding, and acceptability and modified as a result of this feedback.
Phase 2: Delphi Consensus Methods
The questionnaire developed in Phase 1 was sent to stakeholders including CRC surgeons,
clinical nurse specialists, and patients who had undergone surgery for CRC (Round 1).
Patients were considered to be essential stakeholders, as they are the recipients of treatment,
and surgeons and clinical nurses have an in-depth understanding of the potential impact of
surgery. Oncologists were excluded as chemo/radiotherapy was outside the scope of this COS.
Surgeons and nurses were identified from United Kingdom (UK) National Health Service
hospital trusts that routinely performed surgical resection of CRC and participated in the UK
National Bowel Cancer Audit. Nonprobabilistic purposive sampling was conducted to ensure
center variation based upon geographical region (Northern England, the Midlands, Southwest
and Southeast England, and Wales) and caseload volume per annum as determined by
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number of major resections in 2012. Patients were recruited from University Hospitals Bristol
NHS Foundation Trust, North Bristol NHS Trust, and Plymouth Hospitals NHS trust in the
UK. Participants were approached by post and were sent the questionnaire with a stamp-
addressed envelope for return. One reminder was sent if there was no response after four
weeks. Nonprobabilistic purposive sampling was conducted to ensure representation based
on age, sex, and cancer site (rectum, left colon, right colon). Demographic data was collected
including area of deprivation, marital status, employment status, and educational level. Dep-
rivation was defined by the UK Office of National Statistics Index of Multiple Deprivation at
lower layer Super Output Area level for the individual. This is a combined measure of income,
employment, health and disability, education, barriers to public services, crime, and living
environment. Educational level was defined as up to basic education (to the age of 16 or com-
pletion of the UK General Certificate of Secondary Education or equivalent), further educa-
tion (subsequent qualifications to the age of 18 but not degree level), undergraduate, and
postgraduate education.
Questionnaires asked participants to rate the importance of domains on a nine-point Likert
scale, where 1 was a “not essential” and 9 an “absolutely essential” outcome. Returned first
round questionnaires were analyzed, and any outcomes considered least essential were dis-
carded. In Round 2, participants were provided with feedback from Round 1 in the form of
their previous score for each domain and a mean score from their stakeholder group. Partici-
pants were then asked to rescore each domain on the nine-point Likert scale, and the results
were used to determine which domains should be retained and presented in the consensus
meetings. Participants that did not respond to the first questionnaire were ineligible for Round
2 because of the necessity to receive their own feedback. Responses from Round 1 were
accepted until the Round 2 questionnaire was distributed. Round 2 responses were accepted
until the respective stakeholder consensus meeting.
Phase 3: Face-to-Face Consensus Meetings
Three consensus meetings were held; two with health professionals and a third with patients
and caregivers. The first professional consensus meeting was held at the Tripartite Colorectal
Meeting (the combined meeting of the Association of Coloproctology of Great Britain and Ire-
land, the American Society of Colon and Rectal Surgeons, the Royal Society of Medicine, Royal
Australasian College of Surgeons, Colorectal Surgical Society of Australia and New Zealand,
and the European Society of Coloproctology) in Birmingham in 2014. Ongoing discussion pre-
vented the completion of the consensus meeting within the allotted time, and a second was
hosted by the European Society of Coloproctology meeting in Barcelona in 2014. Meetings
were open to all members of international societies and, in addition, all participants of the Del-
phi process were invited to attend. Participants were asked to declare their country of resi-
dence. The patient and caregiver meeting was held in Bristol in 2013. Attendees at this meeting
were all from the UK and had completed the questionnaire surveys and responded to an invita-
tion to attend a consensus meeting.
The retained outcomes from the second survey were presented at the meetings, and partici-
pants were asked to anonymously rate their importance. Anonymized voting took place to ask
participants to vote each outcome as either “In” or “Out” using electronic keypads. Histograms
and descriptive statistics were created live for each outcome during the meeting and displayed
to the participants. Where the similar number of participants voted “In” or ‘“Out,” issues were
explored by discussion to determine the nature of the polarized response within the stake-
holder groups. Dissenting views were actively sought and considered before voting was
completed.
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Sample Size
There are no agreed methods to set the sample size for Delphi surveys or consensus meetings,
and there is no requirement for a statistically representative sample [20]. Therefore, an oppor-
tunistic approach was used with the aim of obtaining approximately 100 respondents for both
the professional and patient stakeholder groups for the survey and a smaller group in which
discussion could take place in the consensus meetings.
Data Analyses
After Round 1 of the survey, outcomes were categorized as “essential” and retained for Round
2 if they were rated between 7 and 9 by over 50% of respondents and between 1 and 3 by less
than 15%. Outcomes not meeting these criteria for either patients or professionals were dis-
carded. Mean scores were calculated for each retained outcome to form the feedback for
Round 2. Round 2 responses were analyzed with stricter cut-off criteria, retaining outcomes
rated between 7 and 9 by over 70% of respondents, and between 1 and 3 by less than 15%.
There are no agreed methods for selecting cut-off criteria within Delphi studies and, therefore,
the criteria were chosen after discussion within the writing group and collaborators within the
COMET initiative.
The outcomes retained after Round 2 were considered in Phase 3 consensus meetings. Dur-
ing the meeting, each outcome was discussed, and voting took place that asked attendees to
vote outcomes as “In,” “Out,” or during the patient meeting, “Unsure.” The “Unsure” category
was included in the patient consensus meeting to ensure that participants understood the ques-
tion. Voting was undertaken using electronic keypads to ensure anonymity, and no data were
collected on participants who changed votes. The unsure items were rediscussed with further
voting and discussion. All items retained from the patient and professional meetings were
included in the final core set. There is no accepted definition of consensus in the literature. The
overall approach in this study was to be inclusive so that outcomes of importance to partici-
pants were not inappropriately excluded from the COS. Therefore, outcome domains were
only excluded if voted “In” by less than 33% of participants. There were deviations from this
analysis. In the first professional consensus, meeting a more conservative approach was taken,
because there was insufficient time for discussion. Domains were only excluded if voted “In”
by less than 25% of participants. In addition, if consensus was not reached after two rounds of
professional voting, a majority rules approach was taken.
Results
Phase 1: Domain Generation
Review of all data sources identified 1,216 outcomes of CRC surgery that were grouped into 91
domains. The domains included outcomes about survival, recurrence, postoperative complica-
tions, and long-term quality of life. A summary of results is presented in Fig 1.
Phase 2: Delphi Process
A total of 81 CRC centers were sampled, of which 63 (78%) responded, including 90 surgeons
and 8 clinical nurse specialists (Table 1). The centers represented all geographical regions of
England and Wales, and caseloads averaged 117 major resections per year (range 38 to 275).
Patient response rate was 97 out of 267 invited (36%). The patients’ age range was wide (29 to
87), sex ratio fairly equal (41 female, 42%), and similar numbers of patients had rectal (33,
35%), left (34, 35%), and right (30, 29%) colonic tumors. Many patients lived in areas of low
deprivation, but there was an even distribution of basic and higher educational level. Health
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professionals rated short-term technical outcomes of greatest importance in Round 1 including
anastomotic leak, adequacy of resection margins, and perioperative mortality (Table 2).
Although these issues were also rated as important to patients, patients gave a major priority to
longer term outcomes such as survival, distant recurrence, and impact on longer term quality
of life. A total of 45 domains met the criteria to be retained for Round 2 (S1 Table).
The response rate in Round 2 was 80% (78/98) for health professionals and 90% (87/97) for
patients. The provision of feedback and more stringent cut-off criteria in Round 2 resulted in
23 domains being retained for consideration in the consensus meetings (S2 Table).
Phase 3: Consensus Meetings
The two professional and one patient/caregiver consensus meetings were attended by 61, 35,
and 14 participants, respectively. Professional demographic details were not completed as
planned and are therefore missing. At the Tripartite colorectal conference, anonymized voting
did not reach a consensus on domains for the core set in the allotted time. Eight domains were
voted “Out” and were discarded. The remainder were considered polarized with support for
inclusion of between approximately 40% and 60% (Table 3), and these were brought forward
to the European Society of Coloproctology meeting. Initial voting in this second meeting iden-
tified four domains to be included into the core set, five to be discarded, and six to be discussed
further. Follow-up voting reached a consensus on including an additional two domains
Fig 1. Flow diagram of Delphi process.
doi:10.1371/journal.pmed.1002071.g001
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Table 1. Participant characteristics.
Clinical centers
Responders (63) Nonresponders (18)
Region (%)
Northern England 14 (22) 5 (28)
Midland 8 (13) 0
Southeast England 22 (35) 10 (55)
Southwest England 9 (14) 0
Wales 10 (16) 3 (17)
Mean number of major colorectal resections (range)a 117 (38 to 275) 90 (29 to 210)
Patients
Responders (n = 97) Nonresponders (n = 170)
Mean age (range) 64 (29 to 87) 68 (29 to 88)
Female (%) 41 (42) 95 (56)
Cancer site (%)
Rectum/anus 33 (35) 55 (32)
Left colon 34 (36) 46 (27)
Right colon 30 (29) 60 (36)
Unknown 9 (5)
IMD quintile (%)b
1 5 (5) 27 (16)
2 13 (13) 38 (23)
3 20 (21) 24 (14)
4 20 (21) 41 (24)
5 39 (40) 23 (23)
Educational level (%)
Basic 30 (32)
Higher 34 (35)
Undergraduate 16 (16)
Postgraduate 6 (6)
Not disclosed 11 (11)
Marital status (%)
Single/divorced 17 (18)
Married/cohabiting 73 (75)
Widowed 7 (7)
Employment status (%)
Employed 16 (17)
Retired 58 (60)
Seeking work 1 (1)
Not working voluntarily 5 (5)
Sickness leave 5 (5)
Other 12 (12)
Length of hospital stay (%)
<2 weeks 80 (83)
2–3 weeks 10 (10)
3–4 weeks 3 (3)
>4 weeks 4 (4)
aNumber of major cancer resections are deﬁned by the UK National Bowel Cancer Audit 2012.
bIMD: Index of Multiple Deprivation as deﬁned by the UK Ofﬁce of National Statistics at lower layer Super Output Area level for the individual. Lower
quintile equates to higher deprivation.
doi:10.1371/journal.pmed.1002071.t001
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Table 2. Top ten highest scored outcome domains after Round 1, by stakeholder group.
Outcome domain n (%) patients rating domain highly
importanta
Outcome domain n (%) professionals rating domain highly
importanta
N = 97 N = 98
Resection margins 88 (91) Anastomotic leak 96 (99)
Stoma rate 84 (87) Resection margins 93 (96)
Distant recurrence 81 (83) Operative mortality 89 (92)
Recurrence 80 (82) Conversion to open
operation
88 (91)
Local recurrence 80 (82) Distant recurrence 87 (90)
Nonprogression 80 (82) Re-operation 87 (90)
Disease free interval 79 (81) Local recurrence 86 (89)
Sphincter
preservation
74 (76) Recurrence 85 (88)
Lymph node yield 72 (74) Lymph node yield 83 (86)
Survival 71 (73) Length of hospital stay 83 (86)
aHigh importance is deﬁned as scoring 7–9 on a nine-point Likert scale.
doi:10.1371/journal.pmed.1002071.t002
Table 3. Voting on outcome domains to be included in the COS in the surgeon consensus meetings.
Tripartite voting N = 61
n (%)*
ESCPa Round 1 voting N = 35 n (%)* ESCPa Round 2 voting N = 35 n (%)*
Outcome domain In Consensus In Out Consensus In Out Consensus
Anastomotic leak 36 (59) Vote again 23 (65) 7 (20) Vote again 20 (57) 14 (40) In
Surgical site infection 29 (48) Vote again 12 (35) 12 (35) Vote again 8 (23) 27 (77) Out
Hemorrhage 13 (21) Out - - - - - -
Visceral injury 9 (14) Out - - - - - -
Conversion to open operation 15 (24) Out - - - - - -
Venous thromboembolism 18 (29) Vote again 4 (10) 28 (80) Out - - -
Bowel obstruction 16 (26) Vote again 7 (21) 23 (67) Out - - -
Abandoning the operation 3 (5) Out - - - - - -
Perioperative mortality 38 (62) Vote again 33 (95) 2 (5) In - - -
Reoperation 43 (71) Vote again 19 (55) 6 (17) Vote again 13 (38) 20 (56) Out
Stoma rate 25 (41) Vote again 14 (40) 15 (42) Vote again 16 (45) 17 (48) Out
Stoma complications 16 (26) Vote again 8 (23) 24 (68) Out - - -
Readmission to hospital 21 (34) Vote again 15 (44) 18 (51) Vote again 8 (23) 30 (77) Out
Cancer recurrence 27 (45) Vote again 32 (90) 2 (5) In - - -
Long-term survival 31 (50) Vote again 28 (80) 5 (15) In - - -
Resection margins 20 (33) Vote again 27 (78) 3 (9) In - - -
Lymph node yield 10 (16) Out - - - - - -
Length of stay in hospital 13 (22) Out - - - - - -
Quality of life 34 (56) Vote again 19 (53) 9 (27) Vote again 25 (71) 9 (26) In
Sexual functioning 21 (34) Vote again 7 (20) 21 (60) Out - - -
Physical functioning 12 (19) Out - - - - - -
Fecal urgency 12 (19) Out - - - - - -
Fecal incontinence 27 (44) Vote again 9 (25) 18 (50) Out - - -
a European Society of Coloproctology
doi:10.1371/journal.pmed.1002071.t003
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(Table 3). The composition of the final health professional core set of outcomes was ratified by
a two-thirds majority.
In initial anonymized voting at the patient consensus meeting, ten domains were voted “In,”
four “Out,” and nine considered for further debate (Table 4). Extensive discussion ensued, and
it was recognized that some domains had overlapping content and meaning. “Physical func-
tion” was therefore grouped with “quality of life,” and “resection margins” was grouped with
“survival.” Follow-up voting reached a consensus on including three more domains into the
core set. Patient and professional COSs were then combined (Box 1). Discussions around peri-
operative mortality were interesting. Patients were aware that CRC surgery typically has a low
operative mortality and did not feel it important to differentiate between early mortality and
survival in the context of identifying the minimum set of core outcomes. It was excluded after
two rounds of voting. Surgeons, conversely, felt perioperative mortality was an important
marker of surgical (technical) success, and it was voted into the COS.
Conclusions
This study has determined a COS to use in trials in CRC surgery. A wide range of sources
including published studies and patient interviews were used to identify the initial long list that
was reduced using consensus methods with professionals and patients to identify 23 domains
Table 4. Voting on outcome domains to be included in the COS in the patient consensusmeeting.
Round 1 voting n (%)a Round 2 voting n (%)a
Outcome domain In Out Unsure Consensus In Out Unsure Consensus
Anastomotic leak 9 (64) 2 (14) 3 (21) Vote again 11 (79) 2 (14) 1 (7) In
Surgical site infection 14 (100) 0 0 In - - - -
Hemorrhage 7 (50) 2 (14) 5 (36) Vote again 1 (7) 10 (71) 3 (21) Out
Visceral injury 8 (57) 3 (21) 3 (21) Vote again 4 (29) 10 (71) 0 Out
Conversion to open operation 12 (86) 1 (7) 1 (7) In - - - -
Venous thromboembolism 7 (50) 4 (29) 3 (21) Vote again 4 (29) 8 (57) 2 (14) Out
Bowel obstruction 5 (36) 5 (36) 4 (29) Vote again 2 (14) 11 (79) 1 (7) Out
Abandoning the operation 4 (29) 7 (50) 3 (21) Out - - - -
Perioperative mortality 7 (50) 5 (36) 2 (14) Vote again 4 (29) 10 (71) 0 Out
Reoperation 3 (21) 8 (57) 3 (21) Out - - - -
Stoma rate 13 (93) 1 (7) 0 In - - - -
Stoma complications 6 (43) 6 (43) 2 (14) Vote again 13 (93) 1 (7) 0 In
Readmission to hospital 5 (36) 8 (57) 1 (7) Out - - - -
Cancer recurrence 9 (64) 4 (29) 1 (7) In - - - -
Long-term survival 10 (71) 4 (29) 0 In - - - -
Resection margins 11 (79) 1 (7) 2 (14) In - - - -
Lymph node yield 7 (50) 6 (43) 1 (7) Vote again 0 13 (93) 1 (7) Out
Length of stay in hospital 0 14 (100) 1 (7) Out - - - -
Quality of life 12 (86) 1 (7) 1 (7) In - - - -
Sexual functioning 7 (50) 3 (21) 4 (29) Vote again 11 (79) 3 (21) 0 In
Physical functioning 10 (71) 4 (29) 0 In - - - -
Fecal urgency 10 (71) 1 (7) 3 (21) In - - - -
Fecal incontinence 10 (71) 2 (14) 2 (14) In - - - -
a Patients voted for whether each domain was in or out of the COS.
doi:10.1371/journal.pmed.1002071.t004
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of the greatest importance. Finally, consensus meetings with surgeons and patients and care-
givers reconsidered the domains and voted on the final COS. It is recommended that all trials
and other nonrandomized studies and audit undertaking of clinical evaluation of CRC surgery
use this COS and further work to establish best instruments with which to measure these out-
comes is underway.
It was not possible to identify other published COSs for CRC surgery. The COMET database
has no other CRC COS development projects registered, although there is ongoing research to
define a COS for anal cancer trials that may be conceptually similar [21]. A COS for use in all
types of adult cancer treatment trials has been developed [22]. This generic cancer COS was
developed with face-to-face consensus meetings with professionals who recommended that 12
symptoms be included in a COS (fatigue, insomnia, pain, anorexia, dyspnea, cognitive prob-
lems, anxiety, nausea, depression, sensory neuropathy, constipation, and diarrhea). It did not,
however, survey patients’ views, which are very important in the evaluation of treatments [23].
Conceptually, it has been argued that patients’ views should be given at least equal if not greater
importance over those of health professionals [24], and it is therefore unclear if this represents
an appropriate COS. Furthermore, the scope of this COS encompasses all cancer treatments in
adults. This broad remit may neglect details that are of specific importance to CRC patients or
indeed patients undergoing surgery.
This study used robust consensus methodology and followed guidelines established by the
COMET initiative to develop a COS, but there are some weaknesses. In Phase 1, the identifica-
tion of large numbers of outcomes from primary data sources mandated the categorization
Box 1. Final COS
Oncological outcomes:
• Long-term survival
• Cancer recurrence
• Resection margins
Operative outcomes:
• Anastomotic leak
• Perioperative survival
• Surgical site infection
• Stoma rates and complications
• Conversion to open operation (where appropriate)
Quality of life:
• Physical function
• Sexual function
• Fecal incontinence
• Fecal urgency
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into domains. This introduces an element of subjectivity that was minimized through indepen-
dent dual categorization, although there is the possibility that some outcomes may have been
inappropriately grouped or separated. This is highlighted by the additional amalgamation of
domains that occurred during the consensus meetings, where participants considered some
domains unnecessarily detailed. In Phase 2, the scope of the Delphi process was limited to the
UK before the COS development process was opened internationally to professionals in Phase
3. This was done to exclude the least important domains without the complexity of a multina-
tional Delphi process; however, different domains may have been brought forward for discus-
sion at the consensus meetings if the first round had included international participation.
Participants at the professional consensus meeting did not report their country of residence as
planned. This was not apparent until after the meeting had concluded, and it is therefore
unclear as to the precise nationalities involved in the process. Further research is therefore
needed to fully validate the COS more widely. This will include liaising with international orga-
nizations including the European Organisation for Research and Treatment of Cancer and the
United States National Cancer Institute.
Another limitation is the numbers of participants involved in the process and response
rates. In particularly, the response rates from patients to the first questionnaire survey was low.
The effect of this on the validity of the Delphi is unclear, because the purpose of the methodol-
ogy is not to garner the views of a representative sample of stakeholders but to gain a consensus
among a wide range of individuals with disparate opinions. In that respect, this study achieved
wide diversity based on a priori patient characteristics. However, it is possible that patients not
responding to the survey may have different opinions of the importance of each item to the
responding group. Similarly, different professional groups, such as medical oncologists and
radiologists, could have been recruited to bring a different perspective to the COS. The scope of
the COS was, however, limited to surgery, and this guided the stakeholder involvement. It is
important to expand the COS to include all treatment modalities in the future, at which point
the involvement of other groups will be critical.
The scope of this COS was intentionally broad and included cancer of the colon and rectum.
Many of the COS domains clearly traverse all colorectal surgery and include oncological out-
comes such as survival, surgical outcomes such as anastomotic leak, and quality of life out-
comes such as physical function. It is acknowledged, however, that patients have different
experiences following surgery for colon or rectal cancer. Problems with sexual or bowel func-
tion, for example, are typically caused by the pelvic dissection and loss of reservoir associated
with rectal surgery and are not usually associated with right-sided colonic surgery. Similarly,
stoma formation is rare following right hemicolectomy. This issue was discussed at length in
the professional consensus meetings and, although most participants agreed on a combined
colorectal COS, some professionals still considered it unresolved. Nonetheless, feedback from
patients suggested that these outcomes were important to measure in all colorectal studies,
because the information was valued. In that respect, a patient undergoing right hemicolectomy
may be concerned about the need for a stoma but reassured by a body of research demonstrat-
ing that stoma rates are low. Ultimately, the decision to have a combined colorectal COS was
based on a patient-centered approach.
This study has defined which outcomes to measure in studies of CRC surgery. The next step
is to identify how these outcomes should be measured in a valid, reliable, and acceptable way.
This was not considered within this study because it is first necessary to assess the quality of
potential outcome measures, a process that could not be undertaken until the COS domains
were defined. One organization championing standards in measurement instruments is COS-
MIN (COnsensus-based Standards for the selection of health Measurement Instruments) [25].
This group uses similar Delphi methods to agree on the taxonomy, terminology, and definition
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of outcomes—a process that will be necessary to further the benefits of this COS. Another
potential benefit of COSs is to provide evidence for use in clinical discussions with patients.
Future research is required to examine how the COS can be included in clinical consultations
to inform patient-centered decision making.
In conclusion, this study used health services research methodology to develop a COS for
use in CRC surgical trials. It is now necessary to validate the use of this set in international
research practice, with the aim of maximizing cross study comparisons, easing meta-analysis,
and minimizing outcome reporting bias. Further work to identify recommended measures to
use to assess each outcome is underway.
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